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reamble
ver the past decade, there has been an increasing awareness
at the quality of medical care in the United States is highly
riable. In its seminal document dedicated to characterizing
ficiencies in delivering effective, timely, safe, equitable,
ficient, and patient-centered medical care, the Institute of
edicine described a quality “chasm” (1). Recognition of the
agnitude of the gap between the care that is delivered and
e care that ought to be provided has stimulated interest in the
velopment of measures of quality of care and the use of such
easures for the purposes of quality improvement and
countability.
Consistent with this national focus on healthcare quality,
e American College of Cardiology Foundation (ACCF) and
e American Heart Association (AHA) have taken a leader-
ip role in developing measures of the quality of care for
rdiovascular disease (CVD) in several clinical areas (Table 1).
he ACCF/AHA Task Force on Performance Measures was
rmed in February 2000 and was charged with identifying
e clinical topics appropriate for the development of perfor-
ance measures and assembling writing committees com-
sed of clinical and methodological experts. When appro-
iate, these committees have included representation from
her organizations involved in the care of patients with the
ndition of focus. The committees are informed about the
ethodology of performance measure development and are
structed to construct measures for use both prospectively
d retrospectively, rely on easily documented clinical crite-
a, and, where appropriate, incorporate administrative data. The
ta elements required for the performance measures are linked
existing ACCF/AHA clinical data standards to encourage
iform measurements of cardiovascular care. The writing
mmittees are also instructed to evaluate the extent to which
isting nationally recognized performance measures conform
the attributes of performance measures described by the
CCF/AHA and to strive to create measures aligned with
ceptable existing measures when this is feasible.
The initial measure sets published by the ACCF/AHA
cused primarily on processes of medical care or actions
ken by healthcare providers, such as the prescription of a
edication for a condition. These process measures are
unded on the strongest recommendations contained in the
CCF/AHA clinical practice guidelines, delineating actions
ken by clinicians in the care of patients, such as the prescrip-
n of a particular drug for a specific condition. Specifically, the
riting committees consider as candidates for measures those
ocesses of care that are recommended by the guidelines either
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administered, or Class III, which identifies procedures/
eatments that should not be administered (Table 2). Class II
commendations are not considered as candidates for per-
rmance measures. The methodology guiding the translation
guideline recommendations into process measures has
en explicitly delineated by the ACCF/AHA, providing
idance to the writing committees (8).
Although they possess several strengths, processes of care
e limited as the sole measures of quality. Thus, current
CCF/AHA Performance Measures Writing Committees are
structed to consider structures of care, outcomes, and
ficiency as complements to process measures. In develop-
g such measures, the committees are guided by methodol-
y established by the ACC/AHA (9). Although implemen-
tion of measures of outcomes and efficiency is currently not
well established as that of process measures, it is expected
at such measures will become more pervasive over time.
Although the focus of the performance measures writing
mmittees is on measures intended for quality improvement
forts, other organizations may use these measures for
ternal review or public reporting of provider performance.
herefore, it is within the scope of the writing committee’s
sk to comment, when appropriate, on the strengths and
itations of such external reporting for a particular CVD
ate or patient population. Thus, the metrics contained within
is document are categorized as either performance mea-
res or test measures. Performance measures are those
etrics that the committee designates as appropriate for use
r both quality improvement and external reporting. In contrast,
st measures are those that have been deemed appropriate for
e purposes of quality improvement but not for external
porting until further validation and testing are performed.
All measures have limitations and pose challenges to
plementation that could result in unintended consequences
hen used for accountability. The implementation of mea-
res for purposes other than quality improvement requires
eld testing to address issues related but not limited to sample
ze, frequency of use of an intervention, comparability, and
ble 1. ACCF/AHA Performance Measurement Sets
pic Original Publication Date
ronic heart failure (2) 2005
ronic stable coronary artery disease (3) 2005
pertension (4) 2005
-elevation and non–ST-elevation myocardial
farction (5)
2006
rdiac rehabilitation (6) 2007
rial fibrillation (7) 2008
imary prevention of cardiovascular disease 2009
ripheral arterial disease 2010*
ACC indicates American College of Cardiology; ACCF, American College of
sociation–Physician Consortium for Performance Improvement; AACVPR, Am
llege of Radiology; SCAI, Society for Cardiac Angiography and Interventions;
ciety for Vascular Nursing; and SVS, Society for Vascular Surgery.
*Planned publication date.dit requirements. The manner in which these issues is thdressed is dependent on several factors, including the
ethod of data collection, performance attribution, baseline
rformance rates, incentives, and public reporting methods.
he ACCF/AHA encourages those interested in implementing
ese measures for purposes beyond quality improvement to
ork with the ACCF/AHA to consider these complex issues in
lot implementation projects, to assess limitations and con-
unding factors, and to guide refinements of the measures to
hance their utility for these additional purposes.
By facilitating measurements of cardiovascular healthcare
ality, ACCF/AHA performance measurement sets may
rve as vehicles to accelerate appropriate translation of
ientific evidence into clinical practice. These documents are
tended to provide practitioners and institutions that deliver
re with tools to measure the quality of their care and
entify opportunities for improvement. It is our hope that
plication of these performance measures will provide a
echanism through which the quality of medical care can be
easured and improved.
Frederick A. Masoudi, MD, MSPH, FACC
Chair, ACCF/AHA Task Force on Performance Measures
. Introduction
he ACCF/AHA Primary Prevention of Cardiovascular Dis-
se Performance Measures Writing Committee (the Writing
ommittee) was charged to develop performance measures
r the prevention of CVD. These performance measures do
t specifically address prevention of stroke, although be-
use risk factors for heart disease and stroke overlap, their
e should contribute to the prevention of stroke as well.
hese measures are intended for adults (18 years of age and
der) evaluated in the outpatient setting. The Writing Com-
ittee designed most of the measures, including all of the
estyle measures, to begin at age 18 because we recognize
at risk for atherosclerosis accumulates over a lifetime and,
though it is never too late to make changes to prevent heart
sease, the greatest benefit accrues with early lifestyle
anges. The relation between cardiovascular risk factors and
Partnering Organizations Status
ACC/AHA—inpatient measures
ACC/AHA/PCPI—outpatient measures
Currently undergoing update
Currently undergoing update
ACC/AHA/PCPI Currently undergoing update
ACC/AHA/PCPI Currently undergoing update
ACC/AHA Updated 2008
AACVPR/ACC/AHA
ACC/AHA/PCPI
ACCF/AHA
ACCF/AHA/ACR/SCAI/SIR/SVM/SVN/SVS
gy Foundation; AHA, American Heart Association; PCPI, American Medical
ssociation of Cardiovascular and Pulmonary Rehabilitation; ACR, American
iety for Interventional Radiology; SVM, Society for Vascular Medicine; SVN,Cardiolo
erican A
SIR, Soce extent and severity of coronary atherosclerosis in the
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September 29, 2009:1364–405 Performance Measures for Primary Prevention of CVDenage years and earlier is well established on the basis of
topsy studies (10,11). Evidence from long-term follow-up
udies demonstrates that a favorable risk factor profile
ring the working years is associated with a longer, healthier
e and reduced medical care expenses after age 65 (12–17).
hese observations indicate the value of prevention of risk
ctors in the first place, beginning in childhood and youth, as
lled for by the AHA’s “Guidelines for Primary Prevention
Atherosclerotic Cardiovascular Disease Beginning in
hildhood” (18). Although the greatest long-term benefit
curs with changes early in life, changes in adults are also
couraged because they have been demonstrated to reduce
sk and prevent heart disease in both middle-aged and older
ults. The Writing Committee also acknowledges that the
eld of primary prevention is rapidly evolving because of the
ble 2. Applying Classification of Recommendations and Level
*Data available from clinical trials or registries about the usefulness/efficacy i
yocardial infarction, history of heart failure, and prior aspirin use. A recommend
any important clinical questions addressed in the guidelines do not lend them
a very clear clinical consensus that a particular test or therapy is useful or
†In 2003, the ACCF/AHA Task Force on Practice Guidelines developed a
commendations have been written in full sentences that express a complete
e rest of the document (including headings above sets of recommendations),
rease readers’ comprehension of the guidelines and will allow queries at thentributions of observational research, registries, and clini- oll trials. Hence, modifications to these performance measures
r primary prevention will be necessary as the field advances.
The Writing Committee designed the performance mea-
res to be applicable to the broadest possible population. A
althy lifestyle is believed to be beneficial across the entire
ectrum of age, race, and sex. With respect to age, however,
e recognize that there comes a time when the benefits of
reening and treatment to avert future events may be of
ited value because life expectancy is limited. Moreover, a
mber of the investigations establishing the benefits of
imary prevention have not included elderly patients. In an
fort to balance the competing interests of applying primary
evention as broadly as possible and being consistent with
her organizations’ age criteria, the Writing Committee
commends the use of the proposed measures for patients
ence
nt subpopulations, such as gender, age, history of diabetes, history of prior
th Level of Evidence B or C does not imply that the recommendation is weak.
o clinical trials. Even though randomized trials are not available, there may
.
suggested phrases to use when writing recommendations. All guideline
, such that a recommendation, even if separated and presented apart from
still convey the full intent of the recommendation. It is hoped that this will
ual recommendation level.of Evid
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years because of a paucity of evidence to support the
easure in an older age group. In addition, there may be
easurement circumstances in which a narrower target age
nge is appropriate, and those who implement measures may
oose to specify an age range that is less broad.
Certain measures, such as blood pressure control, may not be
hievable in all patients. Good blood pressure control is a
allenge for providers in selected patient subsets, including
ose with multiple comorbidities and some older patients with
olated systolic hypertension. In addition, patient adherence to
edical regimens varies for many reasons. The Writing Com-
ittee recognizes that providers may care for patients with
mplex medical and socioeconomic conditions for whom
tainment of target levels for risk factors is difficult. Thus, target
vels for attainment of performance measure goals will vary by
tient population and by practice setting; for internal quality
provement initiatives, they are set by the providers.
.1. Scope of the Problem
r more than a century, CVD has been the number 1 killer
the United States for all but 1 year (1918, in which there
as an influenza pandemic). CVD is the underlying cause of
.3% of all deaths, or 1 of every 2.8 deaths, in the United
ates, according to data from 2004. In 2008, an estimated
0 000 Americans suffered a first coronary attack (this
cludes myocardial infarction and unstable angina). Another
5 000 had a silent, or unrecognized, myocardial infarction.
he total cost of CVD and stroke in the United States for
07 is estimated at $448.5 billion (19).
Given the magnitude of the problem and the financial
rden of CVD, improvements in the quality of primary
evention of cardiovascular disease will lead to substantial
provement in healthcare outcomes. Despite advances and
ide publication and dissemination of prevention guidelines
the cardiovascular literature, the inconsistent application of
st practices does a disservice to patients and leaves many
portunities for improvement in care and systems. Account-
ility at the practice level is 1 step toward more consistent
plication of best practice guidelines and improved clinical
tcomes. The size of the performance measure set may place
burden on the practitioner but reflects the complexity of
VD prevention due to its multifactorial pathogenesis. Many
actitioners are assuming this burden to ensure the quality of
eir practice (20,21). In addition, external groups are en-
ged in quality performance measurement and reporting.
here logical, the Writing Committee has attempted to
stinguish between measures that are appropriate for ac-
untability or public reporting and those that should be used
ly for internal quality improvement.
.2. Structure and Membership of the
riting Committee
he members of the Writing Committee included senior
inicians (physicians and an advanced practice nurse) and
ecialists in internal and family medicine, cardiology, pre-
ntive medicine, and epidemiology. The Writing Committee
so included representatives from the American Academy of
mily Physicians; American Association of Cardiovascular scd Pulmonary Rehabilitation; American College of Physi-
ans; Preventive Cardiovascular Nurses Association; and
enters for Disease Control and Prevention, National Center
r Chronic Disease Prevention and Health Promotion, Divi-
on for Heart Disease and Stroke Prevention.
.3. Disclosure of Relationships With Industry
he work of the Writing Committee was supported exclusively
the ACCF and AHA. Committee members volunteered their
e, and there was no commercial support for the development
these performance measures. Meetings of the Writing Com-
ittee were confidential and attended only by Writing Commit-
e members and staff. Writing Committee members were
quired to disclose in writing all financial relationships with
dustry relevant to this topic according to standard ACCF and
HA reporting policies, and they verbally acknowledged these
lationships to the other members (Appendix A).
.4. Review and Endorsement
etween January 22 and February 22, 2008, the performance
easures document underwent a 30-day public comment
riod, during which ACCF and AHA members and other
alth professionals had an opportunity to review and com-
ent on the text in advance of its final approval and
blication. The official peer and content review of the
cument was conducted simultaneously with the 30-day
blic comment period, with 2 peer reviewers nominated by
e ACCF and 2 nominated by the AHA. We sought addi-
nal comments from clinical content experts and perfor-
ance measurement experts. See Appendix B for relation-
ips with industry and other entities of the peer reviewers.
The ACCF/AHA 2009 Clinical Performance Measures for
imary Prevention of Cardiovascular Disease in Adults was
opted by the respective boards of directors of the ACCF
d AHA in June 2009. These measures will be reviewed for
rrency once annually and updated as needed. They should
considered valid until either updated or rescinded by the
CCF/AHA Task Force on Performance Measures.
. Methodology
he development of performance systems involves identifica-
n of a set of measures that target a specific patient population
served over a particular time period. To achieve this goal, the
CCF/AHA Task Force on Performance Measures has outlined
mandatory sequential steps. Sections 2.1 through 2.5 outline
w the Writing Committee addressed these elements.
.1. Target Population and Care Period
he target population consists of patients 18 years of age or
der. We developed exclusion criteria and upper age limits
r certain measures to further specify the target population.
hese performance measures are intended for primary pre-
ntion in the adult population and do not address prevention
ecific to children and adolescents. More information on
imary prevention for children and adolescents can be found
the AHA “Guidelines for Primary Prevention of Athero-lerotic Cardiovascular Disease Beginning in Childhood” (18).
op
C
ph
18
ou
in
he
ev
vi
pr
re
of
re
m
pr
oc
2
G
m
si
pe
go
se
ad
ca
in
m
2)
m
m
W
m
is
14
si
ca
m
th
an
gr
de
m
pr
to
C
T
an
(b
2
T
Pr
th
th
co
U
tiv
in
fo
da
of
R
1369JACC Vol. 54, No. 14, 2009 Redberg et al.
September 29, 2009:1364–405 Performance Measures for Primary Prevention of CVDThe Writing Committee recognizes that there are many
portunities and healthcare settings for primary prevention of
VD. Thus, these performance measures are aimed at any
ysician or healthcare professional who sees adult patients (age
years and older) at risk for CVD. For this document, the
tpatient care period is defined as the period of care provided
an outpatient setting. An ongoing relationship with the
althcare professional is critical to both the initiation and
entual success of preventive measures. In addition, any single
sit may not provide the opportunity to address the full range of
eventive care required, and in general, the Writing Committee
commends that evidence of at least 2 encounters over a period
1 year be established before the physician is expected to have
sponsibility for primary CVD prevention. However, certain
easures, such as smoking cessation, are so important for
evention that the Writing Committee believed they should
cur even in 1 acute visit over a 2-year period.
.2. Dimensions of Care
iven the multiple potential domains of treatment that can be
easured, the Writing Committee identified the relevant dimen-
ons of care that should be evaluated. We placed each potential
rformance measure into the relevant dimension-of-care cate-
ries. Performance measures selected for inclusion in the final
t and their dimensions of care are summarized in Table 3.
Although the Writing Committee considered a number of
ditional measures that focus on equally important aspects of
re, length and complexity considerations did not allow their
clusion in the present set. Final selection of performance
easures was based on 1) the evidence base for a given measure,
ease/complexity of measurement, and 3) coverage in other
easurement sets. The Writing Committee focused on outcome
Table 3. ACCF/AHA Primary Prevention
Measurement Set: Dimension of Care Meaeasures rather than process measures whenever possible. The Pariting Committee recognized that for some patients, there are
any obstacles to attaining the desired outcome. For example, it
difficult for some patients to attain blood pressures less than
0/90 mm Hg because of medication noncompliance, costs,
de effects, or other reasons. To avoid penalizing clinicians who
re for such patients, the Writing Committee designed perfor-
ance measures that give credit for good faith attempts to attain
e treatment goal (e.g., documentation of the use of at least 2
tihypertensive medications in patients with blood pressures
eater than 140/90 mm Hg), as well for attainment of the
sired outcome. Such a strategy fulfills the goals of perfor-
ance measurement by balancing attainment of targets for blood
essure or lipids with recognition of obstacles despite attention
goals. For internal quality improvement purposes, the Writing
ommittee believed that the standards could be more rigorous.
he final set includes both process measures (risk assessment
d risk factor counseling) and intermediate outcome measures
lood pressure, cholesterol values).
.3. Literature Review
he Writing Committee used the 2002 AHA “Guidelines for
imary Prevention of Cardiovascular Disease and Stroke” as
e primary source for deriving these measures (22). In addition,
e Writing Committee reviewed other more recent guidelines to
nsider the most current available evidence. These included the
S Preventive Services Task Force’s “Guide to Clinical Preven-
e Services” (23), the European guidelines on CVD prevention
clinical practice (24), the AHA’s “Evidence-Based Guidelines
r Cardiovascular Disease Prevention in Women: 2007 Up-
te” (25), the Joint British Societies’ “Guidelines on Prevention
Cardiovascular Disease in Clinical Practice” (26), the Third
eport of the National Cholesterol Education Program Expert
iovascular Disease Performance
Matrixof Card
suresnel on Detection, Evaluation, and Treatment of High Blood
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venth report of the Joint National Committee on Prevention,
etection, Evaluation, and Treatment of High Blood Pressure (28).
.4. Definition of Potential Measures
xplicit criteria exist for the development of performance
easures that accurately reflect quality of care, including
fining the numerators and denominators of potential mea-
res and evaluating their applicability, interpretability, and
asibility. To select measures for inclusion in the perfor-
ance measurement set, the Writing Committee prioritized
e recommendations from the 2002 AHA guidelines for
imary prevention of CVD and stroke (22).
The AHA primary prevention guidelines (22) were drafted
fore the AHA’s adoption of a formal rating system regard-
g the strength of the recommendation and the level of
idence. That system, adopted by the AHA and the ACCF,
ables guideline writing groups to specify the degree to
hich the benefit of the care is likely to outweigh any
tential risk, as well as the level of evidence supporting that
nclusion. In general, ACCF/AHA Class I (benefit 
sk) and Class III (risk greater than or equal to benefit)
dications for therapy identify potential dimensions of care
d processes for performance measurement; however, not all
rformance measures must be based on grade A level of
idence (general consistency of direction and magnitude of
fect from multiple [3 to 5] randomized trials or meta-analyses
ith population risk strata evaluated). In particular, when
nsidering interventions to remove harmful exposures (e.g.,
oking cessation counseling), or to restore norms that
isted during earlier phases of human evolution (e.g.,
creased consumption of fruits, vegetables, and whole grains
d decreased consumption of animal products), the need to
tain evidence from clinical trials is less obligatory than for
commendations to add a pharmaceutical agent to a patient’s
gimen. The Writing Committee recognizes that random-
ed, controlled trials of lifestyle interventions are more
fficult to perform than pharmaceutical trials; however,
estyle behavior change remains the cornerstone of a suc-
ssful prevention strategy. The recommended performance
easures in this document are based on processes of care that
e expected to lead to benefit that far outweighs any potential
sk based on evidence sufficiently strong to support broad
pulation-wide applicability. For some measures, we needed
make recommendations despite the absence of evidence
om randomized, controlled trials that used clinical events
d deaths as outcomes.
The Writing Committee recognizes that performance mea-
res imply performance standards, and there are those who
ay find these implicit standards lower than their own
actice standards, particularly with respect to assessment
equency and target intermediate outcomes, such as choles-
rol and blood pressure. Physicians using these measures to
sess their practice quality are invited to choose more
gressive measure specifications. The measures outlined
rein are geared towards the minimum level of acceptable
rformance rather than optimal care, particularly when used
compare providers or for public reporting. In.5. Selection of Measures for Inclusion in
e Performance Measure Set
om analysis of these recommendations, the Writing Com-
ittee identified potential measures relevant to the primary
evention of CVD and then independently evaluated their
tential for use as performance measures using 8 exclusion
iteria adapted from the “ACCF/AHA Attributes of Perfor-
ance Measures” (Table 4) and the Sample Performance
easure Survey Form and Exclusion Criteria Definitions
ppendix C). As part of this process, the Writing Committee
so evaluated the optimal use of each measure for account-
ility/public reporting (A/PR) versus internal quality im-
ovement (IQI) only. Member ratings of all the potential
easures were collated and discussed by the full Writing
ommittee to reach consensus about which measures should
vance for inclusion in the final measure set and whether
y should be designated as IQI measures. Nineteen potential
easures were advanced initially for full specification to
sess their suitability as performance measures. These were
entually reduced to 13 final measures through an iterative
ocess of repeated surveys within the Writing Committee,
ditional literature review, and detailed group discussions.
he 13 performance measures generally support practices
pected to reduce long-term risk of cardiovascular events.
owever, most patient encounters offer opportunities to
aintain low risk among persons not yet exhibiting increased
sk. Reinforcement of favorable health behavior patterns is
sirable as part of every patient encounter, including those
at do not require specific risk-reducing interventions.
The Writing Committee has designated 2 measures (Global
isk Estimation and Aspirin Use) as appropriate for IQI only.
ble 4. Summary of ACCF/AHA Attributes of
rformance Measures
nsideration Attribute
eful in improving
tient outcomes
Evidence-based
Interpretable
Actionable
easure design Denominator precisely defined
Numerator precisely defined
Validity type
● Face*
● Content†
● Construct‡
Reliability
easure
plementation
Feasibility
● Reasonable effort
● Reasonable cost
● Reasonable time period for collection
erall assessment Overall assessment of measure for
inclusion in measurement set
*The measure intuitively appears to capture what it is intended to capture.
†The extent to which the items comprehensively capture the domain they
e intended to measure.
‡The extent to which the measures correlate with other methods of
antifying the underlying construct.addition, for some measures, separate numerators and/or
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September 29, 2009:1364–405 Performance Measures for Primary Prevention of CVDnominators that may be used in IQI programs have been
ecified in addition to numerators/denominators that are
propriate for use in A/PR programs. In making these
signations, the Writing Committee weighed a number of
ctors, including the strength of evidence for the intervention
the primary prevention population; the availability (or
ck) of evidence in specific subgroups, such as women or
derly patients; the potential for unintended consequences if
ed for A/PR (e.g., incentives to avoid treating sicker or
rder to control patients or to overtreat) and the lack of
sted risk models to adjust for variations across provider
tient populations (especially for measures of intermediate
tcomes, e.g., Blood Pressure Control and Blood Lipid
herapy and Control), which could lead to misleading results
used for A/PR. Although these IQI measures represent
luable tools to aid clinicians in improving quality of care
d enhancing outcomes for patients, they are not ready for
e in A/PR programs until there is further testing and
lidation.
. Primary Prevention of CVD
erformance Measures
.1. Definition of Primary Prevention
r purposes of this document, primary prevention is defined as
evention of the first occurrence of CVD. These measures are
erefore appropriate for all patients without clinical CVD,
cluding those with diabetes mellitus. This measure set is
tended to include asymptomatic individuals with disease iden-
ied only by imaging studies. It does not apply to patients who
ould be included in the existing ACCF/AHA/Physician Con-
rtium coronary artery disease performance measures (3).
.2. Brief Summary of the Measurement Set
able 5 summarizes the ACCF/AHA Primary Prevention of
ardiovascular Disease Performance Measurement Set—
ose measures with the highest level of evidence and support
ong the Writing Committee members. Appendix D pro-
des the detailed specifications for each performance mea-
re, including the numerator, denominator, period of assess-
ent, method of reporting, sources of data, rationale, clinical
commendations, and challenges to implementation.
.3. Data Collection
hese performance measures for primary prevention of CVD
e ideally intended for prospective use to enhance the quality
provement process but may also be applied retrospectively.
e recommend use of a data collection instrument to aid
mpliance and measurement (Appendix E). Individual insti-
tions may modify the sample instrument or develop a
fferent tool based on local practice and standards.
The burden of collection of accurate data may be greater
r certain performance measures because of the inconsistent
d potentially incomplete recording of lifestyle screening
d counseling. This reporting could be facilitated by inclu-
on of specific entry fields for history, physical examination,
d nonpharmacological interventions (such as counseling,
et, or physical activity prescriptions) in electronic health tiocords. Otherwise, electronic health records or retrospective
edical record reviews will miss much of the lifestyle
unseling that occurs during routine clinical practice. These
ould then require prospective data collection as a relatively
rdensome means to collect the lifestyle variables. In
dition, the Writing Committee recognized that there are
fferent levels of counseling but chose to allow any mention
counseling for lifestyle changes to satisfy these perfor-
ance measures, to be consistent with the philosophy that
ese performance measures represent a minimum expecta-
ble 5. ACCF/AHA Primary Prevention of Cardiovascular
sease Performance Measurement Set
rformance
easure Name Measure Description Designation
. Lifestyle/risk
factor
screening
Assessment of lifestyles and risk
factors for development of CVD
A/PR
IQI
. Dietary
intake
counseling
Counseling to eat a healthy diet A/PR
. Physical
activity
counseling
Counseling to engage in regular
physical activity
A/PR
. Smoking/
tobacco use
Risk assessment for smoking and
tobacco use behaviors
A/PR
IQI
. Smoking/
tobacco
cessation
Cessation intervention for active
smoking (tobacco use)
A/PR
. Weight/
adiposity
assessment
Measurement of weight and body
mass index and/or waist
circumference
A/PR
. Weight
management
Counseling to achieve and maintain
ideal body weight
A/PR
IQI
. Blood
pressure
measurement
Measurement of blood pressure in all
patients
A/PR
. Blood
pressure
control
Effective blood pressure control or
combination therapy for patients
with hypertension
A/PR
IQI
. Blood lipid
measurement
Fasting lipid profile performed A/PR
IQI
. Blood lipid
therapy and
control
Proportion of patients who meet
current LDL-C treatment targets OR
who are prescribed 1 lipid
lowering medications at maximum
tolerated dose
A/PR
. Global risk
estimation
Use of a multivariable risk score to
estimate a patient’s absolute risk
for development of coronary heart
disease
IQI
. Aspirin use Aspirin in patients without clinical
evidence of atherosclerotic disease
who are at higher CVD risk
IQI
A/PR indicates accountability/public reporting measures (appropriate for all uses,
luding internal quality improvement, pay for performance, physician ranking, and
blic reporting); CVD, Cardiovascular disease; IQI, internal quality improvement
easures (recommended for use in internal quality improvement programs only;
t appropriate for any other use, e.g., pay for performance, physician ranking, or
blic reporting); and LDL-C, low-density lipoprotein cholesterol.n for good quality care. Other performance measures
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Performance Measures for Primary Prevention of CVD September 29, 2009:1364–405lated to end points that are usually recorded in an electronic
alth record include physical measurements (body weight,
ood pressure), laboratory values (blood lipids), and pre-
ription pharmaceuticals; these would confer relatively low
rdens of data collection. Calculation and recording of
obal risk scores may be enhanced by an electronic health
cord, which can be designed to automatically calculate the
amingham Risk Score or other global risk scores with
ailability of the required risk factor data.
.4. Exclusion Criteria and Challenges
Implementation
he Writing Committee added exclusion criteria, recognizing
at there are justifiable reasons for not meeting the perfor-
ance measures. These reasons, which may be due to patient,
edical, or system factors, should be recorded on the data
llection form. Documentation of such factors should be
couraged to provide data for future research and facilitate
-depth quality improvement in situations in which there are
parent outliers with respect to the number of patients with
edical or patient-centered reasons for exclusion.
Challenges to implementation of the measures are dis-
ssed where applicable. In general, the initial challenge
cing any measurement effort is inadequate documentation.
iscussion of these challenges is not an argument against any
dividual measure. Rather, these discussions are cautionary
tes that draw attention to areas in which additional research
ay enhance the value of the measures.
. Discussion
.1. Sex
he Writing Committee recommends identical screening and
vice for men and women for most cardiovascular risk
ctors, including lifestyle, diet, physical activity, smoking,
d blood pressure. Sex-specific age of onset of cardiac risk
llows from the varying epidemiology of heart disease in
en and women (22,25,27). For men 35 years of age and
der and for women 45 years of age and older, global risk
sessment takes into account the sex-specific levels of risk
that interventions are not sex-specific but rather tailored to
sk. We have recommended sex-specific assessment of
iposity to target patients with waist circumference of 35
ches or more for women and 40 inches or more for men for
ditional intervention. For assessment of lipid therapy and
ntrol, the risk from a family history of CVD is relegated to
ale first-degree relatives younger than 55 years of age and
male first-degree relatives younger than 65 years of age,
hereas the risk associated with low levels of high-density
oprotein cholesterol is defined as less than 40 mg/dL in
en and less than 50 mg/dL in women. We recommend
obal risk screening for all men 35 years of age or older and
r all women 45 years of age or older. Finally, we recom-
end administration of aspirin as preventive therapy for men
ith a 10-year coronary heart disease (CHD) risk of 10% or
ore and for women with 10-year CHD risk of 20% or more,
ven different thresholds of risk and benefit (25,27). an.2. Frequency of Screening
general, a comprehensive assessment of risk factors should
performed at least every 5 years starting at 18 years of age,
d a global risk score should be calculated at least every 5
ars starting at the age of 35 years for men and 45 years for
omen. Those with increased cardiovascular risk, for exam-
e, those with diabetes, cigarette smokers, or those with
esity, should have their risk factors and cardiovascular risk
sessed more frequently.
.3. Risk Screening
umerous observational studies have documented the powerful
sociations of healthy lifestyle choices, such as healthier diet,
eater physical activity, avoidance of smoking, and maintaining
lean body mass, with marked reductions in CVD events
5,29,30). Although limited data indicate that assessment
lone) of diet and physical activity improves outcomes, and
ere are concerns regarding the reliability of patient self-report,
sessment and documentation of these factors are important
eans to help the patient and provider understand the patient’s
sk for CVD, to begin a dialogue regarding healthy lifestyle
oices, and to provide specific counseling regarding risk factor
duction to lower overall risk. Although the addition of
ngitudinal, multicomponent behavioral interventions increases the
fectiveness of clinical recommendations alone regarding healthy
et and physical activity, advice alone has been shown to reduce
k factor levels and overall CHD risk (31,32).
There is no consensus on what constitutes adequate docu-
entation of diet, physical activity, and alcohol use. The
riting Committee believes that physicians and other prac-
ioners should strive to capture the healthy and unhealthy
pects of the patient’s habits to provide counseling and
serve change over time. Although the Writing Committee
d not think that any specific tools should be required for
sessment of diet and physical activity, the Committee noted
e existence of numerous validated measures that could
sist patients and providers in assessing the quality and
antity of diet and physical activity. The numerous dietary
struments range from the extensive Diet History Question-
ire (available at http://riskfactor.cancer.gov/DHQ/) to a
mple nutrition history form that a patient can fill out (33) or
simple question regarding how many servings of fruits and
getables a patient eats on average every day. Likewise,
ere are a variety of validated instruments to help measure
ysical activity frequency and intensity, such as the Inter-
tional Physical Activity Questionnaire (available at http://
ww.ipaq.ki.se/ipaq.htm). Some of these instruments are exten-
ve and are designed for research purposes, but portions of them
ay be useful to clinicians, and many can be self-administered
d are available in a wide variety of languages.
There was not a clear consensus among the Writing
ommittee members regarding assessment and counseling on
cohol in CVD risk. Likewise, although premature CVD in a
tient’s first-degree relative is clearly a risk factor for CVD
4,35), there were concerns regarding the ability of provid-
s to adequately assess and document a family history of
VD given reliance on patient self-report and varying defi-
tions of a positive family history. Therefore, alcohol use
d family history were included for use in internal quality
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September 29, 2009:1364–405 Performance Measures for Primary Prevention of CVDprovement only, not for accountability or public reporting.
onetheless, providers are strongly encouraged to ascertain
levant family history and history of alcohol use as reliably
possible, including verifying diagnoses of premature CVD
ith review of medical records of first-degree relatives if the
tient can obtain them. One widely available tool that can
sist patients and providers in ascertaining and updating
mily history information is the US Surgeon General’s
mily History Initiative (available at http://www.hhs.gov/
milyhistory/). The “My Family Health Portrait” tool on this
eb site is intended to make the process of gathering and
oring family history information easier and more efficient
r both patients and healthcare professionals.
.4. Lifestyle Counseling
onsuming a heart-healthy diet (lower in animal products and
ch in fruits and vegetables, whole grains, low-fat or nonfat
iry products, fish, legumes, poultry, and lean meats; calorie
ntrolled; and moderate in sodium intake), as well as engaging
regular physical activity, lowers an individual’s risk for CVD.
herefore, the Writing Committee strongly believes that diet and
ysical activity counseling is the foundation of primary pre-
ntion. Such counseling has the potential to either reduce or
event the development of risk factors, for example, hyperten-
on, hyperlipidemia, obesity, and diabetes. The Writing Com-
ittee recognizes that clinical trial evidence related to morbidity
d mortality outcomes for lifestyle counseling provided in
edical practice settings is not as robust as the evidence for
her medical therapies; however, strong evidence supports the
portance of diet and activity in the risk of CVD, and
cumulated evidence supports the impact of practice-based
unseling on behaviors (36). The Writing Committee believes
at a performance measure for lifestyle counseling should be
opted despite the lack of definitive evidence for morbidity and
ortality benefits, because such trials are unlikely to be con-
cted, and efforts to restore biological and evolutionary norms
e less likely to introduce harm than are pharmacological
terventions. Given that the adoption of lifestyle changes can
event and treat CVD risk factors, the need for other medical
erapies may be reduced or averted entirely. The Writing
ommittee agreed that unless diet counseling and physical
tivity counseling are put forward as performance measures,
ere is no incentive for clinicians to provide such interventions
patients. Yet, the literature provides evidence that patients
spond favorably when counseling is provided. In a recent
udy (37), physicians who gave brief advice on physical activity
d educational materials showed that patients increased phys-
al activity by 18 minutes per week more than control patients
6 months, and a 4% higher proportion of patients achieved the
inimum recommended physical activity level. Furthermore,
bgroup analyses showed that individuals 50 years of age and
der and those who were given an individual physical activity
escription had even greater success, for example, doubling
eir minutes per week of moderate or vigorous physical activity.
A problem identified by the Writing Committee is that the
inician’s cognitive interactions with patients, for example,
unseling, are undervalued and therefore are not reimbursed
third-party payers. However, the creation of an incentive byming these interactions as performance measures will help reentify barriers to effective counseling and improve the value
aced on these interventions by the reimbursement system.
The Writing Committee acknowledges the challenges as-
ciated with mandating diet and physical activity counsel-
g. First, counseling takes time during an already brief
inician office visit. We encourage clinicians to provide a
rect message to patients and to use available resources to
lp deliver lifestyle information, for example, by giving
em printed educational materials, referring patients to
ww.mypyramid.gov, and handing patients an activity pre-
ription (goal equals 30 minutes of brisk walking 5 days per
eek). Second, as performance measures, diet and physical
tivity counseling must be documented. We encourage
actices to integrate counseling interventions into electronic
edical records or paper form so that such documentation
n be expedited. One obvious concern is that compliance
ith a counseling measure does not provide an understanding
the intensity or quality of the counseling.
.5. Weight Management
ody mass index and waist circumference are the designated
easures for assessment of obesity and abdominal obesity,
spectively. Body mass index has been linked with many
alth outcomes and is the measure most commonly reported
treatment trials. However, studies have also demonstrated
e independent contribution of abdominal obesity to cardio-
scular risk, particularly in blacks (38–40). Therefore, the
riting Committee encourages the assessment of both of
ese simple measurements, but only 1 is necessary to meet
e performance standard. At present, there is no evidence
at defining and managing patients on the basis of the
ncept of metabolic syndrome results in reduced morbidity
d mortality; hence, we focused on the individual risk
ctors and not on the concept of the metabolic syndrome.
.6. Hypertension
ypertension is a major risk factor for the development of
VD. The evidence linking untreated hypertension to in-
eased cardiovascular morbidity is undisputed. However,
erature surveys continue to report suboptimal population-
sed management of hypertension. For example, in the
99–2002 National Health and Nutrition Examination Survey
non-Hispanic whites, 62.9% of patients with hypertension
ere aware of their diagnosis, 48.6% were receiving treatment,
d only 29.8% had their hypertension controlled (41). The
riting Committee elected to develop separate performance
easures that evaluate measurement and control.
Published guidelines differ regarding the age at which
ood pressure assessment should commence. We elected to
e the recommendations of the seventh report of the Joint
ational Committee on Prevention, Detection, Evaluation,
d Treatment of High Blood Pressure (28), which recom-
ends screening beginning at 18 years of age. We chose
0/90 mm Hg as the threshold for satisfactory blood pres-
re control because it is the target blood pressure suggested
the seventh report of the Joint National Committee on
evention, Detection, Evaluation, and Treatment of High
lood Pressure for the general hypertensive population. We
cognize that target blood pressure should be lower for
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chronic kidney disease). Our selected target represents the
inimum degree of control, or floor, that is acceptable as a
rformance measure. We do not mean to imply that lower
rgets are not desirable for special populations.
Controversy remains as to the optimal role of specific classes
antihypertensive medication in the treatment of hypertension.
r example, the seventh report of the Joint National Committee
Prevention, Detection, Evaluation, and Treatment of High
lood Pressure and the European Society of Hypertension differ
ith regard to preferred agents for initial monotherapy. This area
inquiry continues to evolve. Recognizing that individual
ysicians may reasonably choose 1 initial strategy over another
d still comply with published guidelines, we have chosen not
mandate the use of particular antihypertensive drug classes to
tisfy the blood pressure control performance measure. Rather,
e require that blood pressure be below the target or that at least
medications have been prescribed. This allows for different
armacological strategies and also recognizes that blood pres-
re for a subset of patients will remain uncontrolled despite
eatment that includes at least 2 medications. We included the
tter criterion because we did not wish to penalize physicians
hose practices may include more challenging patients or more
tients with refractory hypertension due to case-mix issues. If
ood pressure is not controlled despite antihypertensive medi-
tion, clinicians should assess possible reasons for poor control
.g., patient adherence to recommended treatments) before
anging the choice or dose of medication. Both of our blood
essure measures will require electronic or paper medical
cord reviews. With the exception of patients with hypertension
ho have filled prescriptions for at least 2 antihypertensive
edications, claims data will not adequately capture the infor-
ation necessary to evaluate these performance measures.
.7. Lipid Screening and Control
he Writing Committee had an extensive discussion about
e appropriate age at which lipid screening should be
itiated. The Adult Treatment Panel III guidelines recom-
end lipid screening from age 20 years onward. The US
eventive Services Task Force recommends lipid screening
age 35 years for all men and at age 45 years for women
ho are at increased risk for CHD and does not make a
commendation for or against screening in younger individ-
ls who are not at increased risk for CHD. Some Writing
ommittee members advocated the younger age cutoff,
ting that atherosclerosis originates in youth and progresses
young adults; however, many Writing Committee members
vocated older age thresholds for lipid screening because of
e lack of an evidence base of randomized, controlled trials
younger cohorts documenting that lipid screening at
unger ages results in reduction of cardiovascular events in
e long term. The Writing Committee adopted the older age
resholds as the minimum standard for accountability/public
porting, whereas the internal quality improvement standard
lls for screening at younger ages.
Decisions about lipid-lowering therapy should be based on
individual’s risk for CVD rather than solely on sex or age
7,42). The Writing Committee acknowledges that evidence
limited for women and the elderly (43,44). Such risk posessment requires comprehensive ascertainment and docu-
entation of lipid and nonlipid risk factors. Data on individ-
l risk factors are best synthesized by validated risk scores,
d global risk estimation is thus recommended by current
id-lowering guidelines and included in the present docu-
ent as an internal quality improvement measure (see Sec-
n 4.9). Given the lack of consensus regarding which global
sk assessment instrument most correctly captures risk and
hich time frame for risk estimation is most appropriate, and
cause there are no studies to date that directly demonstrate
perior patient outcomes with formal risk scoring as op-
sed to comprehensive risk factor assessment alone, the
riting Committee has chosen not to designate global risk
timation as a performance measure. Ascertainment of the
ta elements for global risk estimation, however, meets
rformance measure criteria.
Considerations similar to those discussed in detail in the
ction on hypertension treatment and control apply to the
eatment and control of dyslipidemia. Statins are the main-
ay of pharmacological lipid-lowering therapy, but the Writing
ommittee has chosen not to prescribe certain lipid-lowering
gimens in favor of others given the variability of lipoprotein
enotypes and the heterogeneity of patients’ tolerance to
rious medication classes and agents within classes.
.8. Global Risk Estimation
he current framework for assessment of risk for CHD and
e selection of potential patients for drug therapy includes
sessment of absolute risk for CHD in the next 10 years
sed on multivariable equations that include a number of
tablished risk factors. These risk equations have face
lidity and provide excellent discrimination of high-risk
0% or greater), intermediate-risk (10% to 20%), and low-
sk (less than 10%) individuals. Their calibration may vary
pending on differences in event rates and prevalence of risk
ctors between the population from which the equations
ere derived and the population in which they are being
ilized. Limited data indicate that the use of these risk
uations improves outcomes (45,46); this area of research
quires further study. Furthermore, most risk equations focus
10-year risk, whereas it is increasingly recognized that risk
r CHD occurs over one’s lifespan, and low 10-year pre-
cted risk in a young person may not indicate low lifetime
sk (14). Indeed, 10-year risk estimates are universally low,
en in the face of significant risk factor burden (47–49), in
unger men (younger than 35 years of age) and women
ounger than 45 years of age). Therefore, several panels (25,27)
ve recommended consideration of long-term or lifetime risk
timates for younger individuals to help emphasize the impor-
nce of early positive lifestyle changes. Lifetime risks may be
timated for individuals 50 years of age or younger with a
blished simple risk factor stratification scheme (14).
A number of 10-year risk scores are currently available. Of
ese, the 1998 Framingham Risk Score (50) has been assessed
d validated in the broadest range of populations and has the
ost years of follow-up. A modification of this risk score was
opted by the third Adult Treatment Panel of the National
holesterol Education Program for risk assessment for the end
int of nonfatal myocardial infarction or coronary death. A
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September 29, 2009:1364–405 Performance Measures for Primary Prevention of CVDwer version of Framingham 10-year risk scores was published
cently (51) with the added utility of prediction of 10-year
obal CVD risk and specific CVD end points (CHD, stroke,
art failure, and peripheral arterial disease). Although the
riting Committee recommends that documentation of the
amingham 10-year risk estimate be the preferred method of
sessing compliance with this measure (Appendix F), the use of
other risk score is also acceptable if it is relevant to the
tient/population. The Adult Treatment Panel III global risk
timates are for hard CHD (fatal CHD or nonfatal myocardial
farction, but excluding angina pectoris), whereas the 1998
amingham scores that are provided in Appendix F are for total
HD (including angina pectoris), although hard CHD risks can
so be derived. The European SCORE (Systematic Coronary
isk Evaluation) (52) estimates fatal CVD risk, whereas the
eynolds Risk Score (53) estimates women’s risk for CVD
cluding stroke and revascularization.
.9. Stroke Risk Assessment
lobal risk assessment tools such as the Framingham Stroke
ofile for first stroke are also available. Although they have
t been validated as widely as the Framingham CHD risk
sessment tool, external validity has been demonstrated in
uropean cohorts (54–59). On the other hand, the global risk
sessment for CHD is widely used and has been adopted in
e Adult Treatment Panel III guideline. Although the calcu-
tions differ, patients at higher CHD risk will also be at
gher risk for stroke. At this time, we recommend use of a
obal risk assessment tool for CHD or CVD. Consideration
ay also be given to use of the recent Framingham global
VD risk scores and the stroke-specific score (51,54,60,61).
.10. Aspirin Use
lthough the benefits of aspirin therapy to prevent myocar-
al infarction, stroke, and vascular disease death in men and
omen with established CVD are well known, the use of
pirin in primary prevention is less clear. Among men and
omen without CVD, there has been little or no benefit for
pirin in reducing CVD death or all-cause death (62). In a
cent meta-analysis of primary prevention studies, there was
significant 12% relative risk reduction in CVD events with
pirin, which was similar across CHD risk categories (62).
nother meta-analysis of individuals without established
sease reported a sex-specific reduction in cardiovascular
ents (63). Aspirin reduced the risk of myocardial infarction
men and the risk of stroke in women; however, aspirin
gnificantly increased the risk of bleeding in both men and
omen (64). Aspirin did not reduce the risk of cardiovascular
sease in Japanese patients with diabetes in the primary
evention setting unless they were 65 years of age or older
5). The use of aspirin for prevention of CVD in patients
ith diabetes mellitus or peripheral arterial disease remains
clear (63,65). Thus, in patients without cardiovascular
sease, the benefit-risk ratio for aspirin should be carefully
eighed since these patients are at lower baseline CVD than
tients with known atherosclerotic disease and aspirin in-
eases the risk of bleeding (gastrointestinal bleeding and
morrhagic stroke). The updated US Preventive Servicesask Force statement provides an algorithm that clinicians vaay sue to assess the potential benefits and risks of aspirin
erapy (23).
The Writing Committee discussed using an age cut point
wever, because the clinical trial data that examined the use
aspirin for primary prevention according to age cut points
ere based on subgroup analysis, with fewer events occurring
younger individuals, rather than an effect modification by age,
e committee preferred to tailor the use of aspirin according to
vel of CHD risk, consistent with current guideline recommen-
tions. Recent data suggests that those at highest risk (e.g.,
HD risk of 20% or greater) may benefit most in terms of
solute risk reduction with aspirin as their absolute risk is high,
though they are also at higher risk of bleeding (62).
Available evidence, primarily from secondary prevention
udies, shows that low-dose aspirin (75 to 81 mg/d) is adequate
fully inhibit platelet aggregation, although doses of 81 to 325
g/d are typically prescribed (66). Higher doses of aspirin are
sociated with an increased risk of bleeding. Guidelines differ
aspirin dose recommendations for primary prevention (81 to
5 mg/d); however, all 3 guidelines (22,23,25) agree that aspirin is
commended for patients at high risk for CHD. Healthcare provid-
s should consider documenting adverse effects, for example,
eeding complications, with respect to aspirin dose.
.11. Diabetes Mellitus
here is increased risk of developing CHD and stroke in both
pe 1 and type 2 diabetes mellitus. However, opinions are divided
to whether they should be considered as CHD risk equivalents.
e believed the available evidence favored classifying diabetes
a risk factor rather than as a CHD equivalent (67,68).
The literature on the effects of blood glucose control on
sk of developing CHD is mixed. There is strong evidence
at tight control of glucose in type 1 diabetes mellitus
duces the risk of developing nonfatal myocardial infarction,
roke, and CVD by up to 57% (69). The evidence for the
fectiveness of tight glucose control with regard to primary
VD prevention is negative for type 2 diabetes mellitus and
ay even be associated with increased risk (70–73). We
erefore elected not to develop performance measures for
abetes, particularly in light of the fact that the National
iabetes Quality Improvement Alliance has already devel-
ed such measures (74). There is very compelling evidence
studies of patients with type 2 diabetes mellitus that tight
ntrol of blood pressure and of blood cholesterol signifi-
ntly reduces the risk of developing CHD.
.12. Dietary Supplementation
ecause of the lack of an established evidence base support-
g a primary prevention benefit for antioxidant vitamins,
lic acid, coenzyme Q, fish oil capsules, and so on, these
ere not included in these performance measures.
. Conclusions
e believe that these measures will provide a useful tool for the
ared goal of improving care in the critical arena of primary
evention of CVD. Cardiac risk factor reduction has the added
nefit of promoting overall good health, in addition to cardio-
scular health. Current federal mandates have made prevention
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evention in good health. We hope that these ACCF/AHA
etrics and discussion will help the nation achieve our goal of
proving health and health care for all Americans.
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September 29, 2009:1364–405 Performance Measures for Primary Prevention of CVDCHD score sheet for men using total cholesterol or LDL-C categories. Uses age, total cholesterol (or LDL-C), HDL-C, blood
essure, diabetes, and smoking. Estimates risk for CHD over a period of 10 years based on Framingham experience in men
to 74 years of age at baseline. Average risk estimates are based on typical Framingham subjects, and estimates of ideal-
ed risk are based on optimal blood pressure, total cholesterol 160 to 199 mg/dL (or LDL-C 100 to 129 mg/dL), HDL-C of 45
g/dL in men, no diabetes, and no smoking. Use of the LDL-C categories is appropriate when fasting LDL-C measurements
e available. Risk estimates were derived from the experience of the Framingham Heart Study, a predominantly white popu-
tion in Massachusetts.
CHD indicates cardiovascular heart diease; chol, cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C,
w-density lipoprotein cholesterol; and Pts, patients.
Adapted from Wilson et al (50), with permission from Lippincott Williams & Wilkins. Copyright 1998, American Heart Association.
*Hard CHD events exclude angina pectoris.
**Low risk was calculated for a person the same age, optimal blood pressure, LDL-C 100–129 mg/dL or cholesterol
0–199 mg/dL. HDL-C 45 mg/dL for men or 55 mg/dL for women, nonsmoker, no diabetes.
Adapted from: NIH Publ
1402 Redberg et al. JACC Vol. 54, No. 14, 2009
Performance Measures for Primary Prevention of CVD September 29, 2009:1364–405Reprinted from NIH Publication No. 00-4084 (103).BMI indicates body mass index.
ication No. 00-4084 (103).
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